City File: Rise in sight
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.M L Laboratories should receive final official approval for its Dextrin 20 kidney dialysis drug by the end of the year. The shares, which have been as high as 963p but have fallen to below 750p, are expected to rise in anticipation of an announcement. M L says there are 380,000 dialysis patients worldwide - a figure expected to soar with the opening up of Eastern Europe, where renal patients are rarely treated. Dextrin 20 is said to be a cleaner, safer and easier solution to the present, far from perfect, dialysis treatment. M L, if all goes to plan, could just be the next Glaxo.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments